# A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)

> **NCT00000742** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 15 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Atevirdine mesylate
- **DRUG:** Zidovudine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00000742
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1993-10
- **Target enrollment:** 15 (—)
- **Last updated:** 2021-11-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000742, "A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT00000742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*